These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11589915)

  • 1. Activation of complement and contact system in Alzheimer's disease.
    Bergamaschini L; Donarini C; Gobbo G; Parnetti L; Gallai V
    Mech Ageing Dev; 2001 Nov; 122(16):1971-83. PubMed ID: 11589915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.
    Bergamaschini L; Canziani S; Bottasso B; Cugno M; Braidotti P; Agostoni A
    Clin Exp Immunol; 1999 Mar; 115(3):526-33. PubMed ID: 10193429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system.
    Bergamaschini L; Donarini C; Foddi C; Gobbo G; Parnetti L; Agostoni A
    Neurobiol Aging; 2001; 22(1):63-9. PubMed ID: 11164277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease.
    Bergamaschini L; Parnetti L; Pareyson D; Canziani S; Cugno M; Agostoni A
    Alzheimer Dis Assoc Disord; 1998 Jun; 12(2):102-8. PubMed ID: 9651139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.
    Zhou J; Fonseca MI; Pisalyaput K; Tenner AJ
    J Neurochem; 2008 Sep; 106(5):2080-92. PubMed ID: 18624920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide.
    Emmerling MR; Spiegel K; Watson MD
    Immunopharmacology; 1997 Dec; 38(1-2):101-9. PubMed ID: 9476121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma.
    Zamolodchikov D; Chen ZL; Conti BA; Renné T; Strickland S
    Proc Natl Acad Sci U S A; 2015 Mar; 112(13):4068-73. PubMed ID: 25775543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement in Alzheimer's disease pathology.
    Emmerling MR; Watson MD; Raby CA; Spiegel K
    Biochim Biophys Acta; 2000 Jul; 1502(1):158-71. PubMed ID: 10899441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis.
    Velazquez P; Cribbs DH; Poulos TL; Tenner AJ
    Nat Med; 1997 Jan; 3(1):77-9. PubMed ID: 8986745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide.
    Webster S; Bradt B; Rogers J; Cooper N
    J Neurochem; 1997 Jul; 69(1):388-98. PubMed ID: 9202333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain.
    Jiang H; Burdick D; Glabe CG; Cotman CW; Tenner AJ
    J Immunol; 1994 May; 152(10):5050-9. PubMed ID: 8176223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation by cross-linked truncated and chimeric full-length beta-amyloid.
    Cribbs DH; Velazquez P; Soreghan B; Glabe CG; Tenner AJ
    Neuroreport; 1997 Nov; 8(16):3457-62. PubMed ID: 9427307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation.
    Webster SD; Tenner AJ; Poulos TL; Cribbs DH
    Neurobiol Aging; 1999; 20(3):297-304. PubMed ID: 10588577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease.
    Rostagno A; Revesz T; Lashley T; Tomidokoro Y; Magnotti L; Braendgaard H; Plant G; Bojsen-Møller M; Holton J; Frangione B; Ghiso J
    J Biol Chem; 2002 Dec; 277(51):49782-90. PubMed ID: 12388551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A possible new role for Aβ in vascular and inflammatory dysfunction in Alzheimer's disease.
    Zamolodchikov D; Strickland S
    Thromb Res; 2016 May; 141 Suppl 2():S59-61. PubMed ID: 27207427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation.
    Li M; Ager RR; Fraser DA; Tjokro NO; Tenner AJ
    Mol Immunol; 2008 Jun; 45(11):3244-52. PubMed ID: 18400300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes in the kallikrein-kinin and complement system in angiography using non-ionic contrast media].
    Hoffmeister HM; Fuhrer G; Pirschel J; Heller W
    Klin Wochenschr; 1988 Sep; 66(17):760-3. PubMed ID: 3263537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches.
    Chen S; Frederickson RC; Brunden KR
    Neurobiol Aging; 1996; 17(5):781-7. PubMed ID: 8892352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes.
    Wouters D; Brouwer MC; Daha MR; Hack CE
    Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.